Nektar Therapeutics announced positive Phase IIb maintenance data for rezpegaldesleukin (rezpeg) in atopic dermatitis showing high EASI‑75 and EASI‑90 response rates in maintenance dosing cohorts, prompting a near‑doubling of the stock and a $460 million underwritten public offering. The company also reported an agreed induction regimen with the FDA for Phase III plans. Nektar said it will start Phase III later this year, using the 24 µg/kg induction schedule and testing monthly and quarterly maintenance regimens. The data rekindles investor confidence after prior pipeline setbacks and finances rapid progression into registrational testing.